REM-001 is a Proprietary Late Stage Photodynamic Therapy (PDT) Platform
REM-001 has broad utility for the treatment of serious cutaneous oncology indications. REM-001 has been previously studied in four Phase II and/or Phase III clinical trials in patients with cutaneous metastatic breast cancer (CMBC), who had previously received chemotherapy and/or failed radiation therapy.
View Candidate